Pablito Nagpala
Pediatric Endocrinology · Long Beach, CANPI 1306820071
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.5% of the total across 557 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 38 manufacturers, the largest accounting for just 16.8% — the pattern of someone who eats at a lot of different presentations.
Across 557 payments — averaging $19.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Novo Nordisk$910
- Arbor Pharmaceuticals, Inc.$860
- Ascendis Pharma Endocrinology Inc$774
- Dexcom, Inc.$613
- Insulet Corporation$583
- plus $5K from 32 others
What the payments were for
- Speaking & faculty fees$3003%
- Food & beverage$9,99992%
- Education$4534%
- Gifts$591%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 79 | $1,814 |
| Novo Nordisk | 54 | $910 |
| Arbor Pharmaceuticals, Inc. | 49 | $860 |
| Ascendis Pharma Endocrinology Inc | 36 | $774 |
| Dexcom, Inc. | 35 | $613 |
| Insulet Corporation | 33 | $583 |
| Tandem Diabetes Care, Inc. | 11 | $556 |
| Pfizer | 23 | $546 |
| Amphastar Pharmaceuticals, Inc. | 41 | $538 |
| Tolmar, Inc. | 26 | $488 |
| Lilly USA, LLC | 17 | $356 |
| Endo Pharmaceuticals Inc. | 16 | $294 |
| Mannkind Corporation | 15 | $246 |
| Tolmar Pharmaceuticals, Inc. | 22 | $221 |
| Kyowa Kirin, Inc. | 8 | $207 |
| Rhythm Pharmaceuticals, Inc. | 8 | $184 |
| Amgen(2 entities) | 9 | $177 |
| BETA Bionics, Inc. | 7 | $168 |
| Azurity Pharmaceuticals, Inc. | 8 | $154 |
| Sanofi-aventis U.S. LLC | 4 | $124 |
| Abbott | 6 | $123 |
| Vistapharm, Inc. | 13 | $118 |
| Medtronic(2 entities) | 5 | $92 |
| Xeris Pharmaceuticals, Inc. | 5 | $91 |
| AstraZeneca | 4 | $83 |
| Embecta Corp. | 3 | $75 |
| Neurocrine Biosciences, Inc. | 2 | $59 |
| Zealand Pharma US, Inc. | 3 | $58 |
| IBSA Pharma Inc. | 3 | $46 |
| BD | 2 | $45 |
| Ultragenyx Pharmaceutical Inc. | 2 | $44 |
| Biomarin Pharmaceutical Inc. | 2 | $42 |
| Ferring Pharmaceuticals Inc. | 1 | $24 |
| Bigfoot Biomedical Inc | 1 | $23 |
| Sequel Med Tech, LLC | 1 | $22 |
| Sandoz | 1 | $20 |
| Endo USA, Inc. | 1 | $19 |
| Lifescan, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Lupron Depot$412
- t-slim insulin pump$300
- Wegovy$121
How this compares
$10,812 in reported general payments places this provider in the 85th percentile of 168 pediatric endocrinology providers in California.
Other pediatric endocrinology in Long Beach
- Amrit BhangooLong Beach$140K
- Juliana AustinLong Beach$17K
- Gnanagurdasan PrakasamSacramento$805K
- Swati ElchuriVentura$210K
- Karen KleinSan Diego$195K
- Francine KaufmanLos Angeles$184K
- Lynda PolgreenOrange$167K
- Kevin KaisermanWest Covina$150K
- Mitchell GeffnerLos Angeles$129K
- Stephen GitelmanSan Francisco$105K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.